Favipiravir was originally developed through Toyama Chemical Co., Ltd. In 2016, Favipiravir’s patent was granted exclusively in franchise to Zhejiang Hisun Pharmaceutical Co., Ltd. The finished drug was temporarily approved on the Chinese market in February 2020. Since the COVID-19 outbreak, Favipiravir has been highly recommended by the governments of China and Japan and has been used in clinical trials to treat COVID-19 since February. It has now been included in the diagnostic and remedy rules of Saudi Arabia, the United Arab Emirates and many other countries, and has been approved for indications of the disease in Russia and India. Stanford Medicine in the United States (https://www.clinicaltrialsarena.com/news/stanford-favipiravir-covid19-trial/) and the Italian Medicines Agency (AIFA) (https://europost.eu/en/a/view / italy-starts-testing-antiviral-drug-avigan-against-covid-19-27664) have also approved efficacy tests of Favipiravir in the new coronavirus.
The ongoing global multicenter clinical trials of favipiravir in the COVID-19 remedy have demonstrated remarkable efficacy and safety. The effects of Hisun Favipiravir tests compared to other drugs used in the 3rd People’s Hospital virus remedy in Shenzhen showed that those who took Favipiravir became negative in viral nucleic acid testing over a shorter period of time (four days), compared to the control organization (11 days); higher rate of improvement in chest images of 91.43% compared to 62.22%, as well as a higher safety point. Inspiring effects were also observed in the first clinical trials of favipiravir in Russia and Bangladesh: 60% of Russian patients (four0 in total) and four8% (five0 in total) of Bangladeshi patients became negative after four to five days, all with no apparent side effects or appearance effects.
Check the content to download the media: https://www.prnewswire.com/news-releases/hisuns-favipiravir-continuously-supports-the-middle-easts-endeavour-in-fighting-covid-19-301103173.html
SOURCE Zhejiang Hisun Pharmaceutical Co. Ltd.